Claims for Patent: 10,426,780

Summary for Patent: 10,426,780

Title:	Antiviral therapy
Abstract:	The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Inventor(s):	Underwood; Mark Richard (Research Triangle Park, NC)
Assignee:	ViiV Healthcare Company (Wilmington, DE)
Application Number:	15/366,442
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,426,780
Patent Claims:	1. A combination comprising a compound of formula (I) ##STR00005## or a pharmaceutically acceptable salt thereof, and rilpivirine, or a pharmaceutically acceptable salt thereof. 2. The combination according to claim 1 wherein the pharmaceutically acceptable salt of rilpivirine is a hydrochloride salt. 3. The combination according to claim 1 wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 4. A method of treatment of HIV infection comprising administering to a human a therapeutically effective amount of a compound of formula (I) ##STR00006## or a pharmaceutically acceptable salt thereof, and rilpivirine, or a pharmaceutically acceptable salt thereof. 5. The method according to claim 4 wherein the pharmaceutically acceptable salt of rilpivirine is a hydrochloride salt. 6. The method according to claim 4 wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 7. The method according to claim 4, wherein the pharmaceutically acceptable salt of the compound of formula (I) is a sodium salt, and wherein the pharmaceutically acceptable salt of rilpivirine is a hydrochloride salt. 8. A pharmaceutical composition comprising a compound of formula (I) ##STR00007## or a pharmaceutically acceptable salt thereof, and rilpivirine, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier therefor. 9. The pharmaceutical composition according to claim 8 wherein the pharmaceutically acceptable salt of rilpivirine is a hydrochloride salt. 10. The pharmaceutical composition according to claim 8 wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 11. The combination according to claim 1 wherein the combination is administered simultaneously. 12. The combination according to claim 1 wherein the combination is administered sequentially. 13. A method of treatment according to claim 4 wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, and rilpivirine or a pharmaceutically acceptable salt thereof, are administered simultaneously. 14. A method of treatment according to claim 4 wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, and rilpivirine or a pharmaceutically acceptable salt thereof, are administered sequentially. 15. A patient pack comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, and rilpivirine or a pharmaceutically acceptable salt thereof. 16. The method according to claim 7, wherein the compound of formula (I) and the rilpivirine is administered as a unit dosage form. 17. The method according to claim 16, wherein the unit dosage form contains 20 mg to 300 mg of the sodium salt of the compound of formula (I) and 20 mg to 300 mg of rilpivirine hydrochloride.